Apraclonidine in the unlicensed treatment of eyelid ptosis

2019 ◽  
Vol 8 (6) ◽  
pp. 262-265
Author(s):  
Gemma Fromage

Eyelid ptosis is a complication that may occur following injection of botulinum toxin type A. It generally presents within 3–7 days of treatment. A drooping or lowering of the eyelid may be severe to the point that it leads to restriction of vision, or it may be subtle, with just the feeling of a heavy lid or, more typically, difficulty in being able to apply eye make-up. There is currently no licensed treatment for eyelid ptosis. Apraclonidine hydrochloride, commonly known as Iopidine is an alpha-adrenergic receptor agonist and causes the contraction of the Muller's muscle, which may result in an eyelid lift of 1–3 mm. There are factors that may lead to an increased risk of this complication, and there are also ways in which to help prevent it from occurring. Thorough consultations should always be given and practitioners should always ensure that they have in-depth knowledge of facial anatomy and musculature and use good injection technique.

2013 ◽  
Vol 124 (8) ◽  
pp. 517-519 ◽  
Author(s):  
Ian Sayers

Asthma is heterogeneous with respect to clinical presentation, underlying disease mechanisms and response to existing drugs making tailored therapy desirable. Pharmacogenetics, the study of the influence of genetic polymorphisms on drug efficacy and/or adverse effects, is relatively advanced in asthma with replicated genetic associations identified in the main drug classes. In the present issue of Clinical Science, Lipworth and co-workers report a proof-of-concept study and demonstrate that, in asthmatic children carrying the β2-adrenergic receptor gene Arg16 polymorphism, a combination of corticosteroid plus leukotriene receptor antagonist provides superior asthma control (e.g. quality of life scores) compared with corticosteroid plus a long-acting β2-adrenergic receptor agonist as add-on therapy. The basis of these observations is well founded, as it has been demonstrated previously that the Arg16 polymorphism may confer an increased risk of exacerbation following prolonged β2-adrenergic receptor agonist use. These results suggest Gly16Arg genotyping in Caucasian asthma patients may have a role in the clinical management of asthma by influencing the decision of which add-on therapy to prescribe; however, larger studies are required to provide definitive conclusions regarding the clinical utility of this approach.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1146-P
Author(s):  
ALANA O'MARA ◽  
AARON CYPESS ◽  
CHERYL CERO ◽  
JAMES W. JOHNSON ◽  
JOYCE D. LINDERMAN ◽  
...  

2004 ◽  
Vol 53 (2) ◽  
pp. 69-75 ◽  
Author(s):  
Shigemi Yoshihara ◽  
Yumi Yamada ◽  
Toshio Abe ◽  
Osamu Arisaka

Sign in / Sign up

Export Citation Format

Share Document